Compare MLKN & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLKN | PCRX |
|---|---|---|
| Founded | 1905 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 1994 | 2010 |
| Metric | MLKN | PCRX |
|---|---|---|
| Price | $14.58 | $22.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $30.25 |
| AVG Volume (30 Days) | ★ 621.2K | 515.7K |
| Earning Date | 03-25-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | ★ 0.98 | 0.07 |
| Revenue | ★ $3,669,900,000.00 | $541,533,000.00 |
| Revenue This Year | $5.94 | $6.78 |
| Revenue Next Year | $3.78 | $8.54 |
| P/E Ratio | ★ $15.23 | $336.79 |
| Revenue Growth | 1.14 | ★ 26.04 |
| 52 Week Low | $13.77 | $18.80 |
| 52 Week High | $23.18 | $27.64 |
| Indicator | MLKN | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.17 | 41.55 |
| Support Level | $13.81 | $22.13 |
| Resistance Level | $16.34 | $24.20 |
| Average True Range (ATR) | 0.60 | 1.26 |
| MACD | -0.15 | -0.25 |
| Stochastic Oscillator | 0.82 | 8.81 |
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.